FDA halts Moderna's norovirus vaccine trial due to a Guillain-Barré syndrome case under investigation.
Read more
3Z Pharmaceuticals' study reveals amlodipine's potential as a non-stimulant therapy for Attention Deficit Hyperactivity Disorder.
Read more
Gates, Novo Nordisk, and Wellcome launch $50M initiative to combat Antimicrobial Resistance in low- and middle-income countries.
Read more
Innovent's IBI363 gains second FDA Fast Track Designation for Squamous Non-Small Cell Lung Cancer treatment.
Read more
Olympus Partners acquires PAI Pharma, a leader in generic oral liquid medicines, to enhance growth and market presence.
Read more
Pfizer's investigational combo reduces Prostatic Neoplasms progression by 49% in Phase I trial.
Read more
FDA approves Merilog, the first rapid-acting insulin biosimilar, for Diabetes Mellitus treatment, enhancing access to cost-effective insulin options.
Read more
FDA grants Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome after promising trial results.
Read more
Bristol Myers Squibb's Sotyktu shows consistent safety and efficacy over five years in treating moderate-to-severe plaque psoriasis.
Read more
Volta Medical's AI-guided ablation improves Atrial Fibrillation outcomes, achieving 88% symptom-free rate in a major clinical trial.
Read more
Incyclix Bio's INX-315 shows promise in overcoming resistance to CDK4/6 inhibitors in breast and pancreatic cancers.
Read more
InnoCare's Phase III trial of ICP-248 and orelabrutinib for Chronic Lymphocytic Leukemia approved in China.
Read more
FDA approves GSK's PENMENVY vaccine for Meningococcal Groups A, B, C, W, and Y in individuals aged 10-25 years.
Read more
DAAN Biotherapeutics partners with LigaChem for ADC development targeting solid tumors.
Read more
Terrain Biosciences launches to accelerate RNA therapeutics and vaccine development using AI and proprietary manufacturing, raising $9M in seed funding.
Read more
Bambusa Therapeutics raises $90M to advance bispecific antibodies for Immunology and Inflammation Diseases.
Read more
Exelixis reports sustained efficacy of CABOMETYX and Opdivo in advanced Renal Cell Carcinoma after five years.
Read more
Augustine Therapeutics appoints Gerhard Koenig as CEO to lead clinical-stage transition for HDAC6 inhibitors.
Read more
Foresee Pharmaceuticals' Casppian Phase 3 trial for Central Precocious Puberty receives third positive DSMB safety recommendation.
Read more
Seaport Therapeutics' GlyphTM platform enhances lymphatic drug transport, achieving up to 55% absorption for improved therapeutic exposure.
Read more
Bambusa Therapeutics raises $90M to advance bispecific antibodies for immunological and inflammatory conditions.
Read more
Tenet Healthcare reports strong 2024 results with significant revenue growth and strategic hospital divestitures.
Read more
AbbVie and Xilio partner to develop tumor-activated immunotherapies, leveraging Xilio's proprietary technology for cancer treatment.
Read more
Genomic data market to reach $5.89 billion by 2033, driven by precision medicine and innovative profiling tools.
Read more
Quantum-Si to announce 2024 financial results and business update on March 3, 2025.
Read more
